Sravnitel'nyy analiz effektivnosti,bezopasnosti i stoimosti primeneniyarezhimov pemetreksed/tsisplatin,bevatsizumab/gemtsitabin/tsisplatini gemtsitabin/tsisplatin v terapiineploskokletochnogo nemelkokletochnogoraka legkogo pozdnikh stadiy
- Authors: Baraklou K.1, Orlando M.1, Orlov S.1, Rayan N.1, Deyvi P.1, Kanivets Y.1, Khan B.1, Brnabik A.1
-
Affiliations:
- Issue: Vol 14, No 1 (2012)
- Pages: 32-40
- Section: Articles
- URL: https://modernonco.orscience.ru/1815-1434/article/view/29478
- ID: 29478
Cite item
Full Text
Abstract
About the authors
Khelen Baraklou
Mauro Orlando
Sergey Orlov
Narayan Rayan
Piter Deyvi
Yana Kanivets
Baoguang Khan
Alan Brnabik
References
- Wilking N, Högberg D, Kasteng F et al. Benchmarking report of lung cancer care in selected European Countries. Karolinska Institutet/i3 Innovus 2008.
- Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355 (24): 2542-50.
- Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010; 21 (9): 1804-9.
- Scagliotti GV, Parikh P, von PJ et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26 (21): 3543-51.
- Nuijten M, Heigener DF, Bischoff HG et al. Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 2010; 69 (Suppl. 1): s4-10.
- Reck M, von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27 (8): 1227-34.
- Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14 (3): 253-63.
- Bucher HC, Guyatt GH, Griffith LE et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50 (6): 683-91.
- Register of Limit Selling prices on the SLDL. http://grls.rosminzdrav.ru/pricelims.aspx
- Price lists of local distributors. http://www.pharmindex.ru
- In-patient bed-day costs, 2010 State Guarantees Program. http://www.minzdravsoc.ru/docs/government/postan/250
- Pazdur R. Memorandum to the file BLA 125 085 Avastin (bevacizumab). FDA Center for Drug Evaluation and Research 2010. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM237171.pdf%20(2010)
- Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305 (5): 487-94.
- Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Vers. 4.3). Australian Pharmaceutical Benefits Advisory Committee 2008. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbacguidelines-index